Income statement
EUR
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -170M | -146M | -97M | -87M | -54M |
| EBITDA | -169M | -146M | -97M | -87M | -54M |
| Net Income | -176M | -134M | -101M | -76M | -43M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$32.80
-1.83% today
Window Change
+8.75%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharvaris N.V. (PHVS) is a Healthcare stock with a market cap of $1.64B and listed on NASDAQ. The stock last traded around $32.80 and up 8.8% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -19.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -19.8%, free cash flow -13.7% with operating margin 0.0% and ROIC -31.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PHVS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHVS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHVS Max Drawdown
-4.60%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHVS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$42.7M
+44.0% YoY
Free Cash Flow
-$44.7M
+33.5% YoY
Revenue Growth
+0.0%
EPS Growth
-19.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -170M | -146M | -97M | -87M | -54M |
| EBITDA | -169M | -146M | -97M | -87M | -54M |
| Net Income | -176M | -134M | -101M | -76M | -43M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 292M | 281M | 391M | 162M | 209M |
| Total Assets | 301M | 291M | 399M | 168M | 212M |
| Total Liabilities | 30M | 24M | 15M | 18M | 7M |
| Shareholder Equity | 271M | 268M | 384M | 149M | 205M |
| Total Debt | 777K | 861K | 239K | 437K | 250K |
| Net Debt | -291M | -280M | -391M | -161M | -209M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
45M
+33.6% YoY
Capital Expenditures
130K
-4.6% YoY
Free Cash Flow
45M
+33.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-70.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.